In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, CorMedix Inc’s stock clocked out at $10.97, up 3.59% from its previous closing price of $10.59. In other words, the price has increased by $3.59 from its previous closing price. On the day, 0.71 million shares were traded. CRMD stock price reached its highest trading level at $11.0 during the session, while it also had its lowest trading level at $10.41.
Ratios:
To gain a deeper understanding of CRMD’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 3.96. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on March 07, 2025, initiated with a Outperform rating and assigned the stock a target price of $18.
On January 13, 2025, D. Boral Capital started tracking the stock assigning a Buy rating and target price of $15.
On August 26, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $13.Rodman & Renshaw initiated its Buy rating on August 26, 2024, with a $13 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 31 ’24 when Mistry Erin bought 1,500 shares for $9.99 per share. The transaction valued at 14,985 led to the insider holds 52,011 shares of the business.
Hurlburt Elizabeth sold 140,027 shares of CRMD for $1,565,670 on Nov 14 ’24. The EVP now owns 45,397 shares after completing the transaction at $11.18 per share. On Nov 14 ’24, another insider, Hurlburt Elizabeth, who serves as the Officer of the company, bought 140,027 shares for $11.12 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 665628928 and an Enterprise Value of 597098496. For the stock, the TTM Price-to-Sale (P/S) ratio is 54.29 while its Price-to-Book (P/B) ratio in mrq is 10.82. Its current Enterprise Value per Revenue stands at 48.694 whereas that against EBITDA is -11.762.
Stock Price History:
The Beta on a monthly basis for CRMD is 1.34, which has changed by 1.6244018 over the last 52 weeks, in comparison to a change of 0.087141395 over the same period for the S&P500. Over the past 52 weeks, CRMD has reached a high of $13.85, while it has fallen to a 52-week low of $3.03. The 50-Day Moving Average of the stock is 4.26%, while the 200-Day Moving Average is calculated to be 36.41%.
Shares Statistics:
It appears that CRMD traded 1.05M shares on average per day over the past three months and 880100 shares per day over the past ten days. A total of 60.68M shares are outstanding, with a floating share count of 59.25M. Insiders hold about 2.35% of the company’s shares, while institutions hold 37.76% stake in the company. Shares short for CRMD as of 1740700800 were 7876541 with a Short Ratio of 7.53, compared to 1738281600 on 7177892. Therefore, it implies a Short% of Shares Outstanding of 7876541 and a Short% of Float of 12.989999999999998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
